Synchronise: Esomeprazole 20 mg once daily for relief of upper gastrointestinal symptoms associated with continuous use of NSAIDs [nonsteroidal anti-inflammatory drugs] including COX-2 [cyclooxygenase] selective NSAIDs in Dutch general practice: The influence of risk-factors for NSAID-associated GI damage on symptom response

Trial Profile

Synchronise: Esomeprazole 20 mg once daily for relief of upper gastrointestinal symptoms associated with continuous use of NSAIDs [nonsteroidal anti-inflammatory drugs] including COX-2 [cyclooxygenase] selective NSAIDs in Dutch general practice: The influence of risk-factors for NSAID-associated GI damage on symptom response

Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Apr 2008

At a glance

  • Drugs Esomeprazole (Primary)
  • Indications NSAID-induced gastrointestinal damage
  • Focus Therapeutic Use
  • Acronyms SYNCHRONISE
  • Sponsors AstraZeneca
  • Most Recent Events

    • 07 Apr 2008 Status changed from recruiting to completed according to ClinicalTrials.gov.
    • 19 Mar 2008 Status changed from in progress to recruiting according to ClinicalTrials.gov.
    • 08 Sep 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top